Korean Circulation Journal

  • 제47권5호
  • /
  • Pages.644-662
  • /
  • 2017
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times

  • 투고 : 2017.02.21
  • 심사 : 2017.03.27
  • 발행 : 2017.09.30
⟨ 이전 논문 다음 논문 ⟩

초록

Atrial fibrillation (AF) and heart failure (HF) are growing cardiovascular disease epidemics worldwide. There has been an exponential increase in the prevalence of AF and HF correlating with an increased burden of cardiac risk factors and improved survival rates in patients with structural heart disease. AF is associated with adverse prognostic outcomes in HF and is most evident in mild-to-moderate left ventricular (LV) dysfunction where the loss of "atrial kick" translates into poorer quality of life and increased mortality. In the absence of underlying structural heart disease, arrhythmia can independently contribute to the development of cardiomyopathy. Together, these 2 conditions carry a high risk of thromboembolism due to stasis, inflammation and cellular dysfunction. Stroke prevention with oral anticoagulation (OAC) remains a mainstay of treatment. Pharmacologic rate and rhythm control remain limited by variable efficacy, intolerance and adverse reactions. Catheter ablation for AF has resulted in a paradigm shift with evidence indicating superiority over medical therapy. While its therapeutic success is high for paroxysmal AF, it remains suboptimal in persistent AF. A better mechanistic understanding of AF as well as innovations in ablation technology may improve patient outcomes in the future. Refractory cases may benefit from atrioventricular junction ablation and biventricular pacing. The value of risk factor modification, especially with regard to obesity, sleep apnea, hypertension and diabetes, cannot be emphasized enough. Close interdisciplinary collaboration between HF specialists and electrophysiologists is an essential component of good long-term outcomes in this challenging population.

키워드

참고문헌

  1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 2015;131:e29-322.
  2. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-5. https://doi.org/10.1161/01.CIR.0000072767.89944.6E
  3. Hu CY, Wang CY, Li JY, Ma J, Li ZQ. Relationship between atrial fibrillation and heart failure. Eur Rev Med Pharmacol Sci 2016;20:4593-600.
  4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5. https://doi.org/10.1001/jama.285.18.2370
  5. Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol 2016;13:131-47. https://doi.org/10.1038/nrcardio.2015.191
  6. Beyerbach DM, Zipes DP. Mortality as an endpoint in atrial fibrillation. Heart Rhythm 2004;1:B8-18.
  7. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142-7. https://doi.org/10.1016/j.amjcard.2013.05.063
  8. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25. https://doi.org/10.1161/CIRCULATIONAHA.105.595140
  9. Roger VL. Epidemiology of heart failure. Circ Res 2013;113:646-59. https://doi.org/10.1161/CIRCRESAHA.113.300268
  10. Thihalolipavan S, Morin DP. Atrial fibrillation and heart failure: update 2015. Prog Cardiovasc Dis 2015;58:126-35. https://doi.org/10.1016/j.pcad.2015.07.004
  11. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386:154-62. https://doi.org/10.1016/S0140-6736(14)61774-8
  12. Khazanie P, Liang L, Qualls LG, et al. Outcomes of medicare beneficiaries with heart failure and atrial fibrillation. JACC Heart Fail 2014;2:41-8. https://doi.org/10.1016/j.jchf.2013.11.002
  13. Lubitz SA, Benjamin EJ, Ellinor PT. Atrial fibrillation in congestive heart failure. Heart Fail Clin 2010;6:187-200. https://doi.org/10.1016/j.hfc.2009.11.001
  14. Stevenson WG, Tedrow UB, Seiler J. Atrial fibrillation and heart failure. J Atr Fibrillation 2008;1:101.
  15. van Veldhuisen DJ, Aass H, El Allaf D, et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail 2006;8:539-46. https://doi.org/10.1016/j.ejheart.2006.01.015
  16. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI102-10.
  17. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009;119:2516-25. https://doi.org/10.1161/CIRCULATIONAHA.108.821306
  18. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695-703. https://doi.org/10.1016/S0735-1097(98)00297-6
  19. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004. https://doi.org/10.1016/j.jacc.2006.01.060
  20. Schmiegelow MD, Pedersen OD, Kober L, Seibæk M, Abildstrom SZ, Torp-Pedersen C. Incidence of atrial fibrillation in patients with either heart failure or acute myocardial infarction and left ventricular dysfunction: a cohort study. BMC Cardiovasc Disord 2011;11:19. https://doi.org/10.1186/1471-2261-11-19
  21. Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MSOPTIMAAL investigators. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 2005;26:350-6. https://doi.org/10.1093/eurheartj/ehi064
  22. Jons C, Jacobsen UG, Joergensen RM, et al. The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: a CARISMA substudy. Heart Rhythm 2011;8:342-8. https://doi.org/10.1016/j.hrthm.2010.09.090
  23. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study Group. TRAndolapril Cardiac Evalution. Eur Heart J 1999;20:748-54. https://doi.org/10.1053/euhj.1998.1352
  24. Nilsson KR Jr, Al-Khatib SM, Zhou Y, et al. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 2010;96:838-42. https://doi.org/10.1136/hrt.2009.180182
  25. Kober L, Swedberg K, McMurray JJ, et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail 2006;8:591-8. https://doi.org/10.1016/j.ejheart.2005.11.007
  26. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991;84:40-8. https://doi.org/10.1161/01.CIR.84.1.40
  27. O'Neal WT, Salahuddin T, Broughton ST, Soliman EZ. Atrial fibrillation and cardiovascular outcomes in the elderly. Pacing Clin Electrophysiol 2016;39:907-13. https://doi.org/10.1111/pace.12907
  28. Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005;26:1303-8. https://doi.org/10.1093/eurheartj/ehi166
  29. Rivero-Ayerza M, Scholte Op Reimer W, Lenzen M, et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J 2008;29:1618-24. https://doi.org/10.1093/eurheartj/ehn217
  30. Rodriguez CJ, Soliman EZ, Alonso A, et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the multi-ethnic study of atherosclerosis. Ann Epidemiol 2015;25:71-6, 76.e1. https://doi.org/10.1016/j.annepidem.2014.11.024
  31. Thomas KL, Piccini JP, Liang L, et al. Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. J Am Heart Assoc 2013;2:e000200.
  32. Bhatia S, Qazi M, Erande A, et al. Racial differences in the prevalence and outcomes of atrial fibrillation in patients hospitalized with heart failure. Am J Cardiol 2016;117:1468-73. https://doi.org/10.1016/j.amjcard.2016.02.016
  33. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52. https://doi.org/10.1161/01.CIR.98.10.946
  34. Poli D, Antonucci E. Epidemiology, diagnosis, and management of atrial fibrillation in women. Int J Womens Health 2015;7:605-14.
  35. Rodriguez F, Stefanick ML, Greenland P, et al. Racial and ethnic differences in atrial fibrillation risk factors and predictors in women: findings from the women's health initiative. Am Heart J 2016;176:70-7. https://doi.org/10.1016/j.ahj.2016.03.004
  36. Patel RB, Vaduganathan M, Shah SJ, Butler J. Atrial fibrillation in heart failure with preserved ejection fraction: insights into mechanisms and therapeutics. Pharmacol Ther. 2016 [Epub ahead of print].
  37. Lam CS, Rienstra M, Tay WT, et al. Atrial fibrillation in heart failure with preserved ejection fraction: association with exercise capacity, left ventricular filling pressures, natriuretic peptides, and left atrial volume. JACC Heart Fail 2017;5:92-8. https://doi.org/10.1016/j.jchf.2016.10.005
  38. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016;133:484-92. https://doi.org/10.1161/CIRCULATIONAHA.115.018614
  39. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 2013;128:1085-93. https://doi.org/10.1161/CIRCULATIONAHA.113.001475
  40. Pandey A, Kim S, Moore C, et al. Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation. JACC Heart Fail 2017;5:44-52. https://doi.org/10.1016/j.jchf.2016.09.016
  41. Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014;35:3452-62. https://doi.org/10.1093/eurheartj/ehu193
  42. Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003;108:668-71. https://doi.org/10.1161/01.CIR.0000086979.39843.7B
  43. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J 2015;36:3250-7.
  44. Sanders P, Morton JB, Davidson NC, et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 2003;108:1461-8. https://doi.org/10.1161/01.CIR.0000090688.49283.67
  45. Pandit SV, Workman AJ. Atrial electrophysiological remodeling and fibrillation in heart failure. Clin Med Insights Cardiol 2016;10:41-6.
  46. Workman AJ, Pau D, Redpath CJ, et al. Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF. Heart Rhythm 2009;6:445-51. https://doi.org/10.1016/j.hrthm.2008.12.028
  47. Platonov PG. Substrate for development of atrial fibrillation in patients with congestive heart failure: are we close to the answer? Heart Rhythm 2009;6:452-3. https://doi.org/10.1016/j.hrthm.2009.01.014
  48. Yeh YH, Wakili R, Qi XY, et al. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 2008;1:93-102. https://doi.org/10.1161/CIRCEP.107.754788
  49. Lugenbiel P, Wenz F, Syren P, et al. TREK-1 (K2P2.1) K+ channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control. Basic Res Cardiol 2017;112:8. https://doi.org/10.1007/s00395-016-0597-7
  50. Sulzgruber P, Koller L, Winter MP, et al. The impact of $CD4^{+}CD28^{null}$ T-lymphocytes on atrial fibrillation and mortality in patients with chronic heart failure. Thromb Haemost 2017;117:349-56. https://doi.org/10.1160/TH16-07-0531
  51. Redfield MM, Kay GN, Jenkins LS, Mianulli M, Jensen DN, Ellenbogen KA. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000;75:790-5. https://doi.org/10.4065/75.8.790
  52. Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D, Olshansky B. Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol 2015;66:1714-28. https://doi.org/10.1016/j.jacc.2015.08.038
  53. Witt BJ, Gami AS, Ballman KV, et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 2007;13:489-96. https://doi.org/10.1016/j.cardfail.2007.01.009
  54. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 2016;203:660-6. https://doi.org/10.1016/j.ijcard.2015.10.220
  55. Brown LA, Boos CJ. Atrial fibrillation and heart failure: factors influencing the choice of oral anticoagulant. Int J Cardiol 2017;227:863-8. https://doi.org/10.1016/j.ijcard.2016.09.086
  56. Pai RG, Varadarajan P. Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin Cardiol 2007;30:349-54. https://doi.org/10.1002/clc.20107
  57. Gurbel PA, Tantry US. Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. JACC Heart Fail 2014;2:1-14. https://doi.org/10.1016/j.jchf.2013.07.007
  58. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015;17:1192-200. https://doi.org/10.1002/ejhf.343
  59. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962. https://doi.org/10.1093/eurheartj/ehw210
  60. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2014;64:2246-80. https://doi.org/10.1016/j.jacc.2014.03.021
  61. Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 2013;62:108-18. https://doi.org/10.1016/j.jacc.2012.06.046
  62. Miller MA, Gangireddy SR, Doshi SK, et al. Multicenter study on acute and long-term safety and efficacy of percutaneous left atrial appendage closure using an epicardial suture snaring device. Heart Rhythm 2014;11:1853-9. https://doi.org/10.1016/j.hrthm.2014.07.032
  63. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014;12:1988-98.
  64. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-13. https://doi.org/10.1161/01.CIR.0000121736.16643.11
  65. Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the Rate Control versus Electrical Cardioversion (RACE) Study. Am Heart J 2005;149:1106-11. https://doi.org/10.1016/j.ahj.2004.11.030
  66. Guglin M, Chen R, Curtis AB. Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM Trial. Heart Rhythm 2010;7:596-601. https://doi.org/10.1016/j.hrthm.2010.01.003
  67. Dyrda K, Roy D, Leduc H, et al. Treatment failure with rhythm and rate control strategies in patients with atrial fibrillation and congestive heart failure: an AF-CHF substudy. J Cardiovasc Electrophysiol 2015;26:1327-32. https://doi.org/10.1111/jce.12828
  68. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001;142:498-501. https://doi.org/10.1067/mhj.2001.117318
  69. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201-8. https://doi.org/10.1016/j.jacc.2003.11.032
  70. Cadrin-Tourigny J, Shohoudi A, Roy D, et al. Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: an AF-CHF substudy. JACC Heart Fail 2017;5:99-106. https://doi.org/10.1016/j.jchf.2016.10.015
  71. Piccini JP, Allen LA. Heart failure complicated by atrial fibrillation: don't bury the beta-blockers just yet. JACC Heart Fail 2017;5:107-9. https://doi.org/10.1016/j.jchf.2016.12.003
  72. Rich MW, McSherry F, Williford WO, Yusuf SDigitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001;38:806-13. https://doi.org/10.1016/S0735-1097(01)01442-5
  73. Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95:924-30. https://doi.org/10.1136/hrt.2008.158931
  74. Weinfeld MS, Drazner MH, Stevenson WG, Stevenson LW. Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. J Heart Lung Transplant 2000;19:638-43. https://doi.org/10.1016/S1053-2498(00)00123-6
  75. Cadrin-Tourigny J, Wyse DG, Roy D, et al. Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. J Cardiovasc Electrophysiol 2014;25:1306-13.
  76. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) substudy. Circulation 2001;104:292-6. https://doi.org/10.1161/01.CIR.104.3.292
  77. Mohanty S, Mohanty P, Trivedi C, et al. Association of pretreatment with angiotensin-converting enzyme inhibitors with improvement in ablation outcome in atrial fibrillation patients with low left ventricular ejection fraction. Heart Rhythm 2015;12:1963-71. https://doi.org/10.1016/j.hrthm.2015.06.007
  78. Gong M, Zhang Z, Fragakis N, et al. Role of ranolazine in the prevention and treatment of atrial fibrillation: a meta-analysis of randomized clinical trials. Heart Rhythm 2017;14:3-11. https://doi.org/10.1016/j.hrthm.2016.10.008
  79. Khan MN, Jais P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008;359:1778-85. https://doi.org/10.1056/NEJMoa0708234
  80. Ullah W, Ling LH, Prabhu S, et al. Catheter ablation of atrial fibrillation in patients with heart failure: impact of maintaining sinus rhythm on heart failure status and long-term rates of stroke and death. Europace 2016;18:679-86. https://doi.org/10.1093/europace/euv440
  81. Zhao Y, Di Biase L, Trivedi C, et al. Importance of non-pulmonary vein triggers ablation to achieve long-term freedom from paroxysmal atrial fibrillation in patients with low ejection fraction. Heart Rhythm 2016;13:141-9. https://doi.org/10.1016/j.hrthm.2015.08.029
  82. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC Multicenter Randomized Trial. Circulation 2016;133:1637-44. https://doi.org/10.1161/CIRCULATIONAHA.115.019406
  83. Al Halabi S, Qintar M, Hussein A, et al. Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials. JACC Clin Electrophysiol 2015;1:200-9. https://doi.org/10.1016/j.jacep.2015.02.018
  84. Moreno J, Zamorano JL. The CABANA trial. Eur Heart J 2014;35:1908-9.
  85. ClinicalTrials.gov (US). Rhythm control - catheter ablation with or without anti-arrhythmic drug control of maintaining sinus rhythm versus rate control with medical therapy and/or atrio-ventricular junction ablation and pacemaker treatment for atrial fibrillation (RAFT-AF): NCT01420393. Bethesda (MD): ClinicalTrials.gov; 2011.
  86. Marrouche NF, Brachmann JCASTLE-AF Steering Committee. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF) - study design. Pacing Clin Electrophysiol 2009;32:987-94. https://doi.org/10.1111/j.1540-8159.2009.02428.x
  87. Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF Trial). Circ Arrhythm Electrophysiol 2014;7:31-8. https://doi.org/10.1161/CIRCEP.113.000806
  88. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013;61:1894-903. https://doi.org/10.1016/j.jacc.2013.01.069
  89. MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart 2011;97:740-7. https://doi.org/10.1136/hrt.2010.207340
  90. Chen MS, Marrouche NF, Khaykin Y, et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004;43:1004-9. https://doi.org/10.1016/j.jacc.2003.09.056
  91. Gentlesk PJ, Sauer WH, Gerstenfeld EP, et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2007;18:9-14. https://doi.org/10.1111/j.1540-8167.2006.00653.x
  92. Boersma LV, Castella M, van Boven W, et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation 2012;125:23-30. https://doi.org/10.1161/CIRCULATIONAHA.111.074047
  93. Vroomen M, Pison L. Hybrid ablation for atrial fibrillation: a systematic review. J Interv Card Electrophysiol 2016;47:265-74. https://doi.org/10.1007/s10840-016-0183-9
  94. Edgerton Z, Perini AP, Horton R, et al. Hybrid procedure (endo/epicardial) versus standard manual ablation in patients undergoing ablation of longstanding persistent atrial fibrillation: results from a single center. J Cardiovasc Electrophysiol 2016;27:524-30. https://doi.org/10.1111/jce.12926
  95. Fung JW, Yip GW, Zhang Q, et al. Improvement of left atrial function is associated with lower incidence of atrial fibrillation and mortality after cardiac resynchronization therapy. Heart Rhythm 2008;5:780-6. https://doi.org/10.1016/j.hrthm.2008.02.043
  96. Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm 2011;8:1088-94. https://doi.org/10.1016/j.hrthm.2011.02.014
  97. Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol 2012;59:719-26. https://doi.org/10.1016/j.jacc.2011.10.891
  98. Manolis AG, Katsivas AG, Lazaris EE, Vassilopoulos CV, Louvros NE. Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Interv Card Electrophysiol 1998;2:71-6.
  99. Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 2013;1:500-6. https://doi.org/10.1016/j.jchf.2013.06.003

피인용 문헌

  1. Targeting atrial fibrillation promoting atrial structural remodeling: is this a viable strategy in patients with heart failure? vol.391, pp.3, 2018, https://doi.org/10.1007/s00210-018-1463-y
  2. The Timing and Role of Atrial Fibrillation Ablation in Heart Failure Patients vol.12, pp.9, 2017, https://doi.org/10.1007/s12170-018-0587-4
  3. Use of Idarucizumab to Revert the Anticoagulant Effect of Dabigatran in Heart Transplant Surgery: An Institutional Experience vol.2020, pp.None, 2017, https://doi.org/10.1155/2020/6927423
  4. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction vol.106, pp.15, 2017, https://doi.org/10.1136/heartjnl-2019-316219
  5. Multi‐modality machine learning approach for risk stratification in heart failure with left ventricular ejection fraction ≤ 45% vol.7, pp.6, 2017, https://doi.org/10.1002/ehf2.12929
  6. Multi‐parametric system for risk stratification in mitral regurgitation: A multi‐task Gaussian prediction approach vol.50, pp.11, 2017, https://doi.org/10.1111/eci.13321
  7. Clinical course of chronic heart failure with preserved ejection fraction after radiofrequency catheter ablation for atrial fibrillation vol.40, pp.None, 2020, https://doi.org/10.26565/2313-6693-2020-40-14
  8. Sex Differences in the Association between Atrial Fibrillation and 90-Day Adverse Outcomes among Older Adults with Heart Failure: A Retrospective Cohort Study vol.18, pp.5, 2017, https://doi.org/10.3390/ijerph18052237
  9. Impact of Atrial Fibrillation on Acute Coronary Syndrome–Analysis of In-Hospital Outcomes and 30-Day Readmissions vol.46, pp.4, 2017, https://doi.org/10.1016/j.cpcardiol.2020.100764
  10. Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association vol.14, pp.7, 2021, https://doi.org/10.1161/hae.0000000000000078
  11. Heart failure and atrial fibrillation: tachycardia‐mediated acute decompensation vol.8, pp.4, 2017, https://doi.org/10.1002/ehf2.13354